Search Results for: JAMA Psychiatry

In Reply We thank Xie for his comments regarding our study published in a recent issue of JAMA Psychiatry and for drawing attention to several important sociodemographic groups, including those defined by immigrant status, disability status, sexual orientation, and gender identity with limited access to psychotherapy. Given evidence of mental health care inequities across these groups, a better understanding of their trends in outpatient psychotherapy use could inform policies to address critical impediments to mental health care equity.

When I give presentations about JAMA Psychiatry, people often ask me what our “strategy” is and how we decide what papers to publish. I respond that our guiding lights are scientific rigor and clinical relevance. This has never been truer than at the present time, when medical research and practice are under scrutiny like never before. We strive to publish original research that will stand the test of time, informed opinion pieces about current challenges, and insightful review articles taking stock of progress. When we succeed in that goal, our readers recognize that our journal showcases the most impactful developments in our field. In 2024, we published a key phase 3 clinical trial on the first new antipsychotic medication with a nondopaminergic mechanism of action in history (xanomeline-trospium) and a study on the positive impact of GLP-1 receptor agonists on alcohol use disorder outcomes in a national registry. We also covered ongoing debates concerning revisions of psychiatric nosology and continued to cover all aspects of the therapeutic potential and pitfalls of psychedelics and even devoted 3 of our popular podcasts to the topic.

JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.

Mission Statement: To advance the equitable, person-centered, and evidence-based practice of internal medicine through publication of scientifically rigorous, innovative, and inclusive research, review, and commentary that informs dialogue and action with clinical, public health, and policy impact.

US physicians’ elevated risk for depression has been well established in the past decade—however, the risk of physician suicide relative to the general public remains unclear. In this issue of JAMA Psychiatry, Makhija and colleagues use data from 97 915 US suicides from 2017 to 2021, drawn from the US National Violent Death Reporting System, to estimate sex-specific suicide incidence rates among physicians and the general population. The authors’ findings indicate that rates of suicide are higher among female physicians and lower among male physicians compared to sex-matched nonphysicians in the general population.

In Reply We read with interest the Letter from Dr Weathers and colleagues in response to our recent Research Letter in JAMA. The possibility of using whole-plant preparations of Artemisia species is worth pursuing if such use holds promise as a cost-effective and potent antimalarial chemotherapy strategy. It is plausible that additional Artemisia phytochemicals not present in purified artemisinin preparations can synergize with the endoperoxides to enhance antimalarial benefits. The evidence from these authors that such preparations slow the evolution of reduced susceptibility to artemisinin in the rodent malaria Plasmodium yoelii is also intriguing. However, drug selection of P yoelii with artemisinins often produces phenotypes that are not readily heritable and have no well-established genetic basis. Therefore, this model does not suffice as a source of insights into reduced artemisinin susceptibility of P falciparum in humans.

To the Editor Although a recent JAMA Insights article titled “Improving Patient Comprehension Through Explanatory Communication” provided important information, we are writing to correct an inaccurate recommendation.

This JAMA Insights explores how coronary artery calcium and computed tomography calcium scores can improve risk assessment for atherosclerotic cardiovascular disease and inform recommendations for statin therapy.

The Original Investigation titled “Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids: the ALPS Follow-Up Study,” published in the May 21, 2024, issue of JAMA, included errors for the Social Responsiveness Scale t scores that were greater than 65, reported in Tables 2 and 3 and in eTable 4 of Supplement 3. This article was corrected online.

In the Special Communication titled “Organization and Performance of US Health Systems,” published in the January 24, 2023, issue of JAMA, an author affiliation was missing. Zakaria El Amrani’s second affiliation should have been listed as “Kellogg School of Management, Northwestern University, Evanston, Illinois.” This article was corrected online.

Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.

This JAMA Patient Page describes ovarian aging, its effect on fertility, and strategies to address infertility due to ovarian aging.

This JAMA Insights discusses the US Food and Drug Administration approval of Kebilidi, eladocagene exuparvovec, for the treatment of aromatic L-amino acid decarboxylase deficiency in adult and pediatric patients.

This JAMA Insights discusses the recent FDA approval of obecabtagene autoleucel for adults with relapsed or refractory B-cell acute lymphoblastic leukemia and provides regulatory considerations.